---
title: "Mingchen Health plans to repurchase company shares for 30 million to 50 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240991905.md"
description: "Mingchen Health announced plans to repurchase company shares, with an amount between 30 million yuan and 50 million yuan, and the repurchase price not exceeding 23 yuan per share. This move aims to enhance investor confidence, align the company's stock market price with its intrinsic value, and support the company's long-term sustainable development"
datetime: "2025-05-20T09:10:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240991905.md)
  - [en](https://longbridge.com/en/news/240991905.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240991905.md)
generator: "portal-rs"
---

# Mingchen Health plans to repurchase company shares for 30 million to 50 million yuan

According to the announcement from Mingchen Health (002919.SZ), based on the judgment of the company's value and confidence in future development, and focusing on the company's long-term sustainable development and value growth, the company aims to enhance investors' confidence in its investments. In line with the company's development strategy, operational conditions, and financial status, the company plans to repurchase its shares in accordance with the provisions of the Company Law, Securities Law, and the Articles of Association. The repurchase price will not exceed RMB 23 per share (inclusive), and the total amount of funds for the repurchase will not be less than RMB 30 million (inclusive) and not exceed RMB 50 million (inclusive)

### Related Stocks

- [002919.CN](https://longbridge.com/en/quote/002919.CN.md)

## Related News & Research

- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [CDC lifts beneficial stake in Exosens to 11.71% of capital, 13.87% of voting rights](https://longbridge.com/en/news/296499698.md)
- [UNM and ScienceSoft Launch First Statewide WHO Healthy Aging Initiative in US](https://longbridge.com/en/news/296641162.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [Frozen blueberries recall categorized under FDA's highest Class I risk level](https://longbridge.com/en/news/296506599.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**